Recent developments in the management of invasive fungal infections in patients with hematological malignancies

被引:31
作者
Karthaus, M
Cornely, O
机构
[1] Evangel Johannes Krankenhaus, Med Klin 2, D-33611 Bielefeld, Germany
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
关键词
invasive fungal infection; Aspergillosis; antigen assay; antifungals; azoles; echinocandins; Candida; infection;
D O I
10.1007/s00277-004-0986-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite recent advances in the last decade, invasive fungal infections are still associated with a high morbidity and mortality. Invasive fungal infections constitute severe infectious complications in patients with hematological malignancies receiving myelosuppressive chemotherapy or sustained immunosuppression after allogeneic transplant regimens. Following a long period of stagnation, considerable progress has been made during the last 5 years in non-culture-based diagnostics and in the treatment of invasive fungal infections. This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients.
引用
收藏
页码:207 / 216
页数:10
相关论文
共 58 条
[1]  
ALMYROUDIS N, 2003, 43 ICAAC ABSTR AM SO, P457
[2]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]  
BISCHOFF TR, 2003, 43 ICAAC ABSTR AM SO, P348
[4]   Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy - A randomized, controlled trial [J].
Boogaerts, M ;
Winston, DJ ;
Bow, EJ ;
Garber, G ;
Reboli, AC ;
Schwarer, AP ;
Novitzky, N ;
Boehme, A ;
Chwetzoff, E ;
De Beule, K .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) :412-422
[5]   Antifungal prophylaxis for severely neutropenic chemotherapy recipients -: A meta-analysis of randomized-controlled clinical trials [J].
Bow, EJ ;
Laverdiére, M ;
Lussier, N ;
Rotstein, C ;
Cheang, MS ;
Ioannou, S .
CANCER, 2002, 94 (12) :3230-3246
[6]  
BUCHHEIDT D, 2003, 43 ICAAC ABSTR AM SO, P478
[7]   Treatment of severe Candida infections in high-risk patients in Germany:: Consensus formed by a panel of interdisciplinary investigators [J].
Büchner, T ;
Fegeler, W ;
Bernhardt, H ;
Brockmeyer, N ;
Duswald, KH ;
Herrmann, M ;
Heuser, D ;
Jehn, U ;
Just-Nübling, G ;
Karthaus, M ;
Maschmeyer, G ;
Müller, FM ;
Müller, J ;
Ritter, J ;
Roos, N ;
Ruhnke, M ;
Schmalreck, A ;
Schwarze, R ;
Schwesinger, G ;
Silling, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (05) :337-352
[8]   Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies [J].
Cornely, OA ;
Ullmann, AJ ;
Karthaus, M .
BLOOD, 2003, 101 (09) :3365-3372
[9]  
CORNELY OA, 2003, 43 ICAAC ABSTR AM SO, P456
[10]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571